DEA Announces How Much Marijuana, MDMA, Psilocyn, LSD, Mescaline, 5-MeO-DMT, MDA, 2-CB Can Be Produced For Research In 2023
Story by Lara Goldstein
The DEA has shared its final production quotas for research drugs for 2023 and is now aiming for further manufacturing goals of several psychedelic compounds than the already substantial increases regarding 2022 initially proposed, reported Marijuana Moment.
The compounds include marijuana, MDMA, psilocyn, LSD, mescaline, 5-MeO-DMT, MDA, and 2-CB.
The agency stated that it is “committed to ensuring an adequate and uninterrupted supply of controlled substances in order to meet the estimated legitimate medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks.”
As such, 2023’s production quota numbers for psilocyn would go from the original 8,000 grams to 12,000 grams, 5-MeO-DMT from 6,000 to 11,000, MDMA from 8,200 to 12,000 grams, MDA from 200 to 12,000 grams, and 2-CB from 25 to 5,100 grams.
Related video: Recent data shows a decline in marijuana sales (CBS Denver)
In the case of marijuana, the DEA suggested the production of 6.7 million grams -or 14,770 pounds- for medical and scientific purposes, more than double that of 2022. Licensed cultivators can now apply to become federal marijuana suppliers under the National Institute on Drug Abuse (NIDA.)
Several companies have already made recommendations to raise DEA’s 2023 proposed quotas in view of pre-clinical and clinical research particularly for PTSD, TRD, schizophrenia and anxiety.
The proposal also received a comment regarding the creation of “diversified categories” for production and research on psilocybin-containing fungi fruiting bodies/sclerotia/liquid culture similar to cannabis (flower), fruiting body extract (akin to cannabis extract), and psilocybin and psilocyn separately as purified compounds (akin to delta-9-THC), as well as applying that same system for mescaline and other plants, fungi and lifeforms producing these compounds.
But the agency replied stating that the suggestions “do not impact the analysis involved in establishing” the production quotas for each substance.
National CBD day is a relatively new holiday. It is perhaps inevitable that advocates of the cannabinoid would look to celebrate it. After all, there are many other days throughout the year associated with cannabis.
These include April 20 (the famous 420 Day) and National Cannabis Oil Day, which falls on July 10. It is also called 710 Day.
Hempsmart™ Smart Relief helps soothe sore, aching muscles, and joints with a synergistic combination of natural botanicals and full spectrum hemp extract, featuring CBD, CBG, and a broad range of active terpenes.
Cannabis & CBD Biopharma Industry Companies Present July 9th, 2020 – REPLAY of Investor Conference & Webinar
In case you missed the event! Access archived webcast presentations from the June 24thKCSA Cannabis Virtual Investor Conferenceon-demand. Watch presentations from leaders and innovators of publicly traded companies in the cannabis sector.
Watching the archived recordings and downloading materials is complimentary for all registrants.
Cannabis Company Executives share vision, answer questions live at the Live Webinar.
NEW YORK, July 7, 2020 /PRNewswire/ — Virtual Investor Conferences today announced the agenda for the upcoming Cannabis & CBD Industry Virtual Investor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET, with the first live webcast at 10:30 AM ET, on Thursday, July 9th. There are no fees to log-in, watch the live presentations and the Q & A.
July 9th, 2020 Agenda: Eastern Time (ET) – Company Name (Ticker)
12:30 PM Marijuana Company of America, Inc.(OTCQB: MCOA) Jesus Quintero, Chairman of the Board of Directors, CEO & CFO Gloria Albarran Lynch, Chief Marketing Officer Robert L Hymers, Strategic Advisory Board for MCOA
“Inspirational Technologies” is an affiliate of HempSMART, a Subsidiary of MCOA